Skip to main content

Table 1 Characteristics of 77 SPN patients with malignant behavior (distant metastasis, recurrence and/or invasion) in the literature

From: Multidisciplinary treatment of advanced or recurrent solid pseudopapillary neoplasm of the pancreas: three case reports

Patient characteristics Number of patients References
Age, median years (range) 24 (7–66)* [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
Male/female/unknown 8 / 54 / 15 [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
Location of main tumor, head/body or tail/unknown 13 / 36 / 28 [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
Metastatic and recurrent site (%)   
 Liver 44 (57.1) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
 Lung 3 (3.9) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
 Peritoneum 19 (24.7) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
 Lymph node 9 (11.7) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
 Local 18 (23.4) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
 Others 6 (7.8) [4, 6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35]
Non-surgical treatment effect, tumor reduction/no response/missing data (total number)   
 GEM-based regimen 0 / 6 / 4 (10) [10, 17, 19, 21, 23, 29]
 CDDP-based regimen 2 / 2 / 2 (6) [10, 17, 18]
 5-FU-based regimen 0 / 3 / 2 (5) [8, 10, 20]
 CDDP + 5-FU 2 / 0 / 3 (5) [10, 25, 26]
 Interferon 0 / 1 / 2 (3) [10, 32]
 Tamoxifen 0 / 2 / 0 (2) [8, 10]
 GEM + CDDP 1 / 1 / 0 (2) [10, 31]
 Somatostatin 0 / 1 / 0 (1) [10]
 Capecitabine 0 / 1 / 0 (1) [10]
 Paclitaxel 0 / 1 / 0 (1) [19]
 Thalidomide 0 / 1 / 0 (1) [10]
 Imatinib 0 / 1 / 0 (1) [10]
 Oxaliplatin-based regimen 0 / 1 / 0 (1) [10]
 Erlotinib 0 / 1 / 0 (1) [23]
 RFA 0 / 3 / 4 (7) [7, 10, 17]
 RT 5 / 0 / 0 (5) [22, 32,33,34,35]
 CRT 0 / 1 / 1 (2) [10]
 TAI 0 / 1 / 1 (2) [10, 23]
 TACE 1 / 0 / 1 (2) [8, 23]
 HIPEC 0 / 1 / 1 (2) [11, 30]
 TAE 0 / 1 / 0 (1) [10]
 MCN 0 / 1 / 0 (1) [10]
 SIRT 0 / 0 / 1 (1) [17]
 CS-PHP 1 / 0 / 0 (1) [31]
 Proton beam therapy 1 / 0 / 0 (1) [29]
  1. GEM gemcitabine, CDDP cisplatin, 5-FU 5-fluorouracil, RFA radiofrequency ablation, RT radiation therapy, CRT chemoradiotherapy, TAI transcatheter arterial infusion, TACE transcatheter arterial chemoembolization, HIPEC hyperthermic intraperitoneal chemotherapy, TAE transcatheter arterial embolization, MCN microwave coagulo-necrotic therapy, SIRT selective internal radiation therapy, CS-PHP chemosaturation with percutaneous hepatic perfusion
  2. *Only 62 patients' data were available